Dana­her strikes deal to buy boom­ing next-gen man­u­fac­tur­er Alde­vron for $9.6B

Life sci­ences con­glom­er­ate Dana­her Corp. $DHR has struck a deal to buy the fast-grow­ing Alde­vron, one of the world’s top man­u­fac­tur­ers of hot­ly sought-af­ter plas­mid DNA, mR­NA and re­com­bi­nant pro­teins for the bur­geon­ing world of vac­cine and drug­mak­ers push­ing some game-chang­ing tech­nolo­gies.

Buy­out talks set the stage for Dana­her to set­tle on a $9.6 bil­lion cash pact to ac­quire the pri­vate Far­go, ND-based com­pa­ny — a key sup­pli­er for a dis­rup­tive new Covid vac­cine as well as a host of gene and cell ther­a­py and CRISPR gene edit­ing play­ers — found­ed by Michael Cham­bers and CSO John Bal­lan­tyne as a crew of 2 back in 1998.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER